Literatur
- 1
Aranda E, Anton-Torres A, Sastre J. et al .
Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
Clin Colorectal Cancer.
2001;
1
43-46
- 2
Ardalan B, Chua L, Tian E M. et al .
A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin
in colorectal carcinoma.
J Clin Oncol.
1991;
9
625-630
- 3
Douillard J Y, Cunningham D, Roth A D. et al .
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line
treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet.
2000;
355
1041-1047
- 4
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B.
Association of tumour site and sex with survival benefit from adjuvant chemotherapy
in colorectal cancer.
Lancet.
2000;
355
1745-1750
- 5
Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf I G.
Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody
dependent cellular cytotoxicity of monoclonal antibody 17 - 1A.
Z Gastroenterol.
2000;
38
615-622
- 6
Giacchetti S, Itzhaki M, Gruia G. et al .
Long-term survival of patients with unresectable colorectal cancer liver metastases
following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and
surgery.
Ann Oncol.
1999;
10
663-669
- 7
Giacchetti S, Perpoint B, Zidani R. et al .
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin
as first-line treatment of metastatic colorectal cancer.
J Clin Oncol.
2000;
18
136-1347
- 8
Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden P O. The Nordic Gastrointestinal
Tumor Adjuvant Therapy Group .
Quality of life during chemotherapy in patients with symptomatic advanced colorectal
cancer.
Cancer.
1994;
73
556-562
- 9
Glimelius B, Jakobsen A, Graf W. et al. Nordic Gastrointestinal Tumour Adjuvant Therapy
Group .
Bolus injection (2 - 4 min) versus short-term (10 - 20 min) infusion of 5-fluorouracil
in patients with advanced colorectal cancer: a prospective randomised trial.
Eur J Cancer.
1998;
34
674-678
- 10
Heald R J, Moran B J, Ryall R D, Sexton R, MacFarlane J K.
Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978 - 1997.
Arch Surg.
1998;
133
894-899
- 11
Hurwitz H, Fehrenbacher L, Cartwright T. et al .
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs
survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab
in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line
therapy in subjects with metastatic CRC.
Proc ASCO.
2003;
22
3646
- 12
Kapiteijn E, Marijnen C A, Nagtegaal I D. et al .
Preoperative radiotherapy combined with total mesorectal excision for resectable
rectal cancer.
N Engl J Med.
2001;
345
638-646
- 13
Kemeny M M, Adak S, Gray B. et al .
Combined-modality treatment for resectable metastatic colorectal carcinoma to the
liver: surgical resection of hepatic metastases in combination with continuous infusion
of chemotherapy-an intergroup study.
J Clin Oncol.
2002;
20
1499-1505
- 14
Lee J H, Ahn J H, Bahng H. et al .
Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer
to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.
J Clin Oncol.
2002;
20
1751-1758
- 15
Lokich J J, Ahlgren J D, Gullo J J, Philips J A, Fryer J G.
A prospective randomized comparison of continuous infusion fluorouracil with a conventional
bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program
Study.
J Clin Oncol.
1989;
7
425-432
- 16
Mandel J S, Church T R, Bond J H. et al .
The effect of fecal occult-blood screening on the incidence of colorectal cancer.
N Engl J Med.
2000;
343
1603-1607
- 17
Maughan T S, James R D, Kerr D J. et al .
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal
cancer: a multicentre randomised trial.
Lancet.
2003;
361
457-464
- 18
Minsky B D, Cohen A M, Kemeny N. et al .
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy
for unresectable rectal cancer.
Int J Radiat Oncol Biol Phys.
1993;
25
821-827
- 19
Moertel C G, Fleming T R, Macdonald J S. et al .
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage
III colon carcinoma: a final report.
Ann Intern Med.
1995;
122
321-326
- 20
Nelson R L, Persky V, Turyk M.
Determination of factors responsible for the declining incidence of colorectal cancer.
Dis Colon Rectum.
1999;
42
741-752
- 21
NIH consensus conference .
Adjuvant therapy for patients with colon and rectal cancer.
JAMA.
1990;
264
1444-1450
- 22
Nordic Gastrointestinal Tumor Adjuvant Therapy Group .
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal
cancer: a randomized trial.
J Clin Oncol.
1992;
10
904-911
- 23
Nordlinger B, Vaillant J C, Guiguet M. et al .
Survival benefit of repeat liver resections for recurrent colorectal metastases:
143 cases. Association Francaise de Chirurgie.
J Clin Oncol.
1994;
12
1491-1496
- 24
O’Connell M J, Martenson J A, Wieand H S. et al .
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil
with radiation therapy after curative surgery.
N Engl J Med.
1994;
331
502-507
- 25
Patt Y Z, Mavligit G M.
Arterial chemotherapy in the management of colorectal cancer: an overview.
Semin Oncol.
1991;
18
478-490
- 26
Poon M A, O’Connell M J, Moertel C G. et al .
Biochemical modulation of fluorouracil: evidence of significant improvement of survival
and quality of life in patients with advanced colorectal carcinoma.
J Clin Oncol.
1989;
7
1407-1418
- 27
Porschen R, Bermann A, Loffler T. et al .
Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected
stage III colon cancer: results of the trial adjCCA-01.
J Clin Oncol.
2001;
19
1787-1794
- 28
Punt C JA, Nagy A, Douillard J Y. et al .
Edrecolomab (17 - 1A Antibody) alone or in combination with 5-Fluorouracil based
chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a phase
III study.
Proc ASCO.
2001;
20
487
- 29
Ribic C M, Sargent D J, Moore M J. et al .
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based
adjuvant chemotherapy for colon cancer.
N Engl J Med.
2003;
349
247-257
- 30
Riethmüller G, Holz E, Schlimok G. et al .
Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome
of a multicenter randomized trial.
J Clin Oncol.
1998;
16
1788-1794
- 31
Salonga D, Danenberg K D, Johnson M. et al .
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of
dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res.
2000;
6
1322-1327
- 32
Saltz L B, Cox J V, Blanke C. et al. Irinotecan Study Group .
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
N Engl J Med.
2000;
343
905-914
- 33
Saltz L, Rubin M, Hochster H. et al .
Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal
cancer (CRC) that expresses epidermal growth factor receptor (EGFR).
Proc ASCO.
2001;
20
7
- 34
Schmoll H, Köhne C, Lorenz M. et al .
Weekly 24 hInfusion of High-Dose (HD) 5-Fluorouracil (5-FU24h) with or Without Folinic
Acid (FA) vs. Bolus 5-FU/FA (NCCTG/Mayo) in Advanced Colorectal Cancer (CRC): A Randomized
Phase III Study of the EORTC GITCCG and the AIO.
Proc ASCO.
2000;
19
935
- 35
Scheithauer W, Rosen H, Kornek G V, Sebesta C, Depisch D.
Randomised comparison of combination chemotherapy plus supportive care with supportive
care alone in patients with metastatic colorectal cancer.
BMJ.
1993;
306
752-755
- 36
Simmonds P C. Colorectal Cancer Collaborative Group .
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis.
BMJ.
2000;
321
531-535
- 37
Stangl R, Altendorf-Hofmann A, Charnley R M, Scheele J.
Factors influencing the natural history of colorectal liver metastases.
Lancet.
1994;
343
1405-1410
- 38
Steele G, Bleday R, Mayer R J, Lindblad A, Petrelli N, Weaver D.
A prospective evaluation of hepatic resection for colorectal carcinoma metastases
to the liver: Gastrointestinal Tumor Study Group Protocol 6584.
J Clin Oncol.
1991;
9
1105-1112
- 39
Tournigand C, Louvet C, Quinaux E. et al .
FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal
cancer (MCRC): final results of a phase III study.
Proc ASCO.
2001;
20
494
- 40
Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C.
A systematic review of the effects of screening for colorectal cancer using the faecal
occult blood test, hemoccult.
BMJ.
1998;
317
559-565
- 41
Twelves C.
Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large,
phase III trials.
Eur J Cancer.
2002;
38
15-20
Priv.-Doz. Dr. D. Flieger
Medizinische Klinik II, Klinikum Aschaffenburg
Am Hasenkopf
63739 Aschaffenburg
